Pharmacokinetics of Promethazine Hydrochloride After Administration of Rectal Suppositories and Oral Syrup to Healthy Subjects

Laura C. Strenkoski-Nix, James Ermer, Sheryl Decleene, William Cevallos, and Philip R. Mayer


Am J Health Syst Pharm. 2000;57(16) 

In This Article


The pharmacokinetics of promethazine administered in oral syrup and rectal suppositories were highly variable, but, in general, the suppositories produced a lower Cmax and later tmaxthan the syrup. All the formulations were comparable in terms of dose-normalized AUC and t1/2, and the three suppository treatments were comparable in terms of dose- normalized Cmax.

[a] Phenergan 12.5-mg rectal suppository, Wyeth-Ayerst Laboratories, Radnor, PA, lot 9940524.
[b] Phenergan 25-mg rectal suppository, Wyeth-Ayerst, lot 9940432.
[c] Phenergan 50-mg rectal suppository, Wyeth-Ayerst, lot 9940315.
[d] Phenergan Syrup Fortis syrup, Wyeth- Ayerst, lot 0940824.
[e] Fleet enema (16 g per 100 mL of monobasic sodium phosphate and 6 g per 100 mL of dibasic sodium phosphate, Johnson & Johnson, Guelph, Ontario).
[f] Vacutainer tubes, Becton Dickinson and Company, Franklin Lakes, NJ.
[g] Electrochemical detector, BAS Analytics, West Lafayette, IN.
[h] Zorbax Rx-C 8 column, 4.6 x 250 mm, Hewlett-Packard, Newport, DE.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.